



ORIGIN

THERAPEUTICS

CORPORATE PRESENTATION
JULY 2021

AN ACTIVELY MANAGED GLOBAL PSYCHEDELIC-FOCUSED
INVESTMENT OPPORTUNITY

CSE: ORIG*
* Proposed Ticker



Disclaimer

THIS PRESENTATION IS CONFIDENTIAL AND IS BEING SUPPLIED TO YOU SOLELY FOR YOUR INFORMATION AND MAY NOT BE REPRODUCED, FURTHER DISTRIBUTED TO ANY OTHER PERSON OR PUBLISHED, IN WHOLE OR IN PART, FOR ANY PURPOSE.

This Presentation does not constitute an offer to sell or a solicitation of offers to buy shares or other securities (“Securities”), assets or products of any company or to invest in any fund and is not intended to form the basis of any investment decision. It is not and shall not be construed as a Private Placement Memorandum, and it is not reviewed or regulated by MiFID, AIFMD, or any other financial authority at this stage.

Although reasonable care has been taken to ensure that the facts stated in this Presentation are accurate and that the opinions expressed are fair and reasonable, the contents of this Presentation have not been verified by any company referred to herein or any other person. Accordingly, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information and opinions contained in this Presentation, and no reliance, should be placed on such information or opinions. Further, the information in this Presentation is not complete and may change. No company referred to herein nor any of their respective members, directors, officers or employees nor any other person accepts any liability whatsoever for any loss howsoever arising from any use of such information or opinions or otherwise arising in connection with this Presentation.

This Presentation is directed only at, and may only be communicated to, (i) persons who are outside the United States within the meaning of Regulation S under the US Securities Act of 1933, as amended (the “US Securities Act”) or (ii) inside the United States to persons who are “accredited investors” as defined in Regulation D under the US Securities Act. No public offering of any securities discussed herein is being made in the United States and the information contained herein does not constitute an offering of securities for sale in the United States and no company is currently intending to register any securities under the US Securities Act. Neither the United States Securities and Exchange Commission nor any securities regulator body of any state or other jurisdiction of the United States, nor any securities regulatory body of any other country or political subdivision thereof, has passed on the accuracy or adequacy of the contents of this Presentation. Any representation to the contrary is unlawful. Persons who do not fall within any of these definitions should not rely on this Presentation or take any action in relation to it. The distribution of this Presentation in other jurisdictions may also be restricted by law, and persons into whose possession this Presentation comes should inform themselves about, and observe, any such restrictions.

Recipients of this Presentation are not to construe its contents, or any prior or subsequent communications from or with any company referred to herein or their representatives as investment, legal or tax advice. In addition, this Presentation does not purport to be all-inclusive or to contain all of the information that may be required to make a full analysis of the relevant company or fund. Recipients of this Presentation should each make their own independent evaluation of the relevance and adequacy of the information in this Presentation and should make such other investigations as they deem necessary. By participating in and/or accepting delivery of this Presentation you agree to be bound by the foregoing restrictions and the other terms of this disclaimer. This Presentation may contain forward-looking statements that reflect current expectations regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors.



Investment Highlights

Origin Therapeutics is an actively-managed investment issuer providing investors with a diverse exposure to the psychedelic industry.

The psychedelic space is a \$100 billion market opportunity¹ and the vast majority of companies created to capture this opportunity are private companies.

Retail investors often do not have access to the most promising private deals. Origin's team of experienced investment professionals has significant deal flow and a process to select the most optimal companies representing the psychedelic industry.

¹Research by Tania Gonsalves, Analyst at Cannacord Genuity. "Around the Corner" (May 2020)





\$100 Billion Market Opportunity

Innovations in medicine are shifting the perspective of mental illness and addiction.

Despite commercial success of conventional medications to treat mental illness and addiction, many leading experts have been disappointed in their efficacy.

1 in 5 Canadians experience a mental illness or addiction problem every year, and by the age of 49, 1 in 2 have—or have had—a mental illness.¹

Mental illness is the leading cause of disability in Canada, and are more likely to cause people to die prematurely than the general population, cutting 10-20 years from a person’s life expectancy.^{2,3,4,5}

¹Smetanin et al. (2011). The life and economic impact of major mental illnesses in Canada: 2011-2041. Prepared for the Mental Health Commission of Canada. Toronto: RiskAnalytica.

²Institute for Health Metrics and Evaluation (2015). *Global Burden of Diseases, Injuries, and Risk Factors Study, 2013*. Data retrieved from <http://www.healthdata.org/data-visualization/gbd-compare>.

³Mental Health Commission of Canada (2014). Why investing in mental health will contribute to Canada’s economic prosperity and to the sustainability of our health care system. Retrieved from <http://www.mentalhealthcommission.ca/English/node/742>.

⁴Lim et al. (2008). A new population-based measure of the burden of mental illness in Canada. *Chronic Diseases in Canada*, 28: 92-8.

⁵Chesney, Goodwin and Fazel (2014). Risks of all-cause and suicide mortality in mental disorders: a meta-review. *World Psychiatry*, 13: 153-60.

⁶Facts and figures from Atai Life Sciences and research by Tania Gonsalves, Analyst at Cannacord Genuity. “Around the Corner” (May 2020)

GLOBAL ADDRESSABLE MARKET⁶

164M PEOPLE AFFECTED BY SUBSTANCE ABUSE

264M PEOPLE AFFECTED BY ANXIETY

300M PEOPLE AFFECTED BY POST-TRAUMATIC STRESS

322M PEOPLE AFFECTED BY DEPRESSION

1.05B TOTAL NUMBER OF PEOPLE POTENTIALLY BENEFITING FROM PSYCHEDELICS




Many companies have emerged in recent years

PUBLIC			<h2>Increasingly competitive landscape</h2> <p>Hundreds of companies have emerged to take advantage of this \$100 billion market opportunity.</p> <h2>Retail investors often have little access</h2> <p>The most promising companies in the psychedelic space are often privately held and raise capital from sophisticated investors.</p> <h2>Early investors reap significant rewards</h2> <p>Early investors in those companies reap significant rewards when they eventually go public.</p>
	PRIVATE		
	WELLNESS	CLINICAL	



Retail investors often do not have access to a great company until it goes public



Investment Strategy

Our experienced team of technical and experienced investment professionals has decades of experience managing investment portfolios and have access to a diverse deal pipeline.

A time-tested due diligence process has been implemented to optimize the pipeline to filter out only the most lucrative opportunities.

We go even further by supporting the companies we invest in with advisory or board positions.





A Robust Strategy Guided by HEAL Principles



The industry developing now has the potential for more than just profitable investments: it's a way to further treatment in mental health. We're investing in a diverse portfolio with one commonality: the betterment of all of us.

Knowing the market, is winning the market. Our in-house expertise and relationships with industry specialists allows us to make decisions from a position of strength.

Brokering partnerships with key players gives us VIP access to exclusive opportunities not available to the public.

The most important asset we have is our team. This powerhouse group brings the insight, analysis, and executive skill backed by decades of successful multi-billion dollar projects.



Execution Capabilities are Second to None

The founding shareholders and board of directors of Origin are founders or early investors in these companies.


They have been personally involved in creating more than \$100 Billion in market value.





Significant Deal Flow from a Well-Connected Management Team

Our **investment mandate** is to focus on companies with an **exemplary team** and **exponential growth** profile.





Origin has Key Advantages over Ordinary ETFs

	ORIGIN THERAPEUTICS	HORIZONS PSYCHEDELIC ETF
DIVERSIFIED PORTFOLIO	✓ (Private & Public)	✓ (Public only)
MANAGEMENT FEE	✗	✓ (0.85%)
BOARD REPRESENTATION	✓	✗
DUE DILIGENCE PRIOR TO INVESTMENT	✓	✗

*Most up-to-date information about the Horizons Psychedelic ETF (PSYK) investment methodology and fees can be found at www.horizonsetf.com



Management



Alexander Somjen

Chief Executive Officer, Director

Alexander Somjen has extensive experience serving as an officer and director of publicly listed and privately held companies across a broad range of sectors including technology, healthcare and cannabis. Most recently, Alexander served as President of a publicly traded, California based multi-state cannabis company and CEO of a publicly traded global investment company. Prior to that, Alexander spent over a decade in capital markets at a large financial institution working in both investment banking and sales and trading related capacities. Alexander holds an MBA from IE Business School.



Management



Kelvin Lee

Chief Financial Officer

Mr. Lee has over 15 years of extensive financial management experience with publicly traded companies. He is formerly CFO of Freeman Gold Corp. and prior, had progressively senior roles from Corporate Controller, VP Finance and Administration to Chief Financial Officer, for a TSXV listed gold producer with \$400 million in revenue over nine years. His responsibilities included development and execution of financial strategy and operations, including regulatory reporting, financial planning and analysis, treasury, tax and audit. He also held prior Controller positions in the mining industry with various publicly traded companies including Prodigy Gold Inc. that was acquired for \$340 million. Kelvin is currently CFO and Director of MegaWatt Lithium and Battery Metals Corp.; and CFO and Director of Karam Minerals Inc.; and CFO of Mantaro Silver Corp. Mr. Lee is a CPA, CGA (British Columbia).



Management



Alfred Wong VP Investments

Alfred is a venture capitalist and entrepreneur with experience in a wide range of sectors including technology, cannabis, and consumer goods. Alfred is currently the Managing Director at Alfred & Company Advisors Inc, a boutique management consulting firm. Alfred was previously President & CEO of a public technology company listed on the Canadian Securities Exchange, and was a former President and Director of Growmax Capital.

In 2017, Alfred co-founded Nash Pharmaceuticals, an innovative drug-repurposing company, focusing in the developing drugs in the areas of non-alcoholic steatohepatitis, chronic kidney, and inflammatory bowel diseases. Nash was acquired by Algernon Pharmaceuticals in 2018 after successful pre-clinical and phase 1 trials.

Between 2016-2019, Alfred was President at Bullrun Capital where he conducted M&A due diligence, fundraising, and RTO transactions for private and public companies. Between 2011 and 2016, Alfred was an entrepreneur executive for several startups in Asia in the areas of financial technology and logistics.

Prior to his entrepreneurship ventures, Alfred supported the transportation & logistics equity research team at Credit Lyonnais Securities Asia in Hong Kong.



Board of Directors



Michael Young Chairman

Mr. Young serves as our Chairman. Mr. Young is a founding partner of Cottingham Capital, an investment company focused on real estate, technology and Consumer brand investments. He has served at Cottingham as Managing Partner since its inception in January 2017.

Prior to January 2017, Mr. Young served as the Managing Director and Co-Head of Trading for a Canadian Investment bank. Mr. Young was previously on the boards of Nuuvera Corp. and ICC Labs. We believe Mr. Young's qualifications to serve as a director of our Company include his extensive senior level executive management, and trading experience, in the Canadian and U.S. capital markets, as well as his experience serving on other public company boards of directors.



Board of Directors



Brianna Davies Independent Director

Ms. Davies is a corporate securities lawyer with over 14 years experience working as legal counsel, corporate secretary and chief compliance officer to various privately held and publicly traded companies, primarily focused in the resource and technology sectors. Brianna has a broad range of international experience having held roles with companies with assets in North America, South America, Russia, Australia, Mali, Ethiopia and Burkina Faso. Brianna obtained a Juris Doctorate from the University of Toronto, Faculty of Law in 2005 and graduated Summa Cum Laude with an Honours B.A in Economics, from McMaster University in Hamilton, Canada in 2002. Brianna is a native English speaker with French language proficiency.



Advisors

Kyle Gould, CFA

Kyle Gould is a Co-Founder of Hyperion Capital Inc., a boutique advisory firm specializing in the Healthcare and Technology Sectors. Prior to Hyperion, Kyle served as a Director within GMP Securities L.P.'s cannabis practice where he aided in raising and advising over \$10 billion worth of corporate mandates across 100+ transactions. During his time at GMP, the firm was ranked #2 globally for cannabis activity. Kyle held roles for GMP in both New York City and Toronto. He started his career at BMO Capital Markets Corp. in New York where he focused on leveraged finance for North American based companies.

Kyle is a CFA Charterholder and graduated from Dalhousie University with a major in Finance.

Jaiveer Singh

Jaiveer Singh is the CEO at Mint Pharmaceuticals. Under his leadership, Mint has emerged as one of the country's most reputable and leading generic pharmaceutical companies over the past decade. Jaiveer is also an active early stage Investor passionate about supporting fellow entrepreneurs in building differentiated and high-quality businesses and currently serves on several boards. He was the Chairman of Truverra until acquired by The Supreme Cannabis Company in 2019 and is a Co-founder of Los Angeles based hedge fund Medina Singh Partners.

Jonathan S. Goldman

Jonathan is an accomplished real estate and infrastructure developer as well as business builder with over 25 years of work experience. Jonathan started his career in commercial real estate and subsequently founded, built, and sold one of the country's most successful renewable energy development firms. He then joined Stafford Developments and became the president and co-owner in 2015. Stafford is a diversified private property development company that carries out land development, construction, and property management with its sister company Goldman Group. Stafford and Goldman have deployed over \$1Bn of equity capital with current managed assets over \$2Bn on behalf of investors. As a result, Jonathan brings a wealth of experience funding and executing the physical build out of many technically advanced facilities. Jonathan has recently been involved in founding multiple new businesses including a cannabis venture fund, a technology infrastructure business, a publicly traded international cannabis production company, a Canadian retail platform and a hospitality company.



Capitalization

SHARES OUTSTANDING	
FOUNDERS / BOARD OF DIRECTORS / MANAGEMENT	34,000,000
\$5M+ FINANCING @ \$0.25 ¹	20,000,000+
TOTAL	54,000,000
OPTIONS	5,400,000
TOTAL DILUTED	59,400,000

¹Financing is structured as a \$0.25 special warrant. The Company intends to use the proceeds of the financing for investments, general working capital, and listing on a publicly-traded stock exchange.



Investment Summary

\$100 billion market opportunity

driven by new medical innovations in treating mental illness and substance abuse with psychedelics.

Many companies have emerged

to take advantage of this opportunity and are raising early seed capital from sophisticated venture capitalists.

Origin provides early access

to privately-held, rapidly growing companies in the psychedelic space.

Diversified portfolio

of companies to maximize exposure to the psychedelic industry while managing risk.

Origin has a Powerhouse Team

The members of Origin's Board and management team have been involved in some of the fastest growing companies in their respective industries.

Origin knows how to grow companies

Origin actively manages its investments through board representation and/or advisory roles.

¹Research by Tania Gonsalves, Analyst at Canacord Genuity. "Around the Corner" (May 2020)



ORIGIN
THERAPEUTICS

CORPORATE PRESENTATION
MAY 2021

A GLOBAL PSYCHEDELIC-FOCUSED INVESTMENT OPPORTUNITY

www.originpsychedelics.com

info@originpsychedelics.com

CSE: ORIG*